For Healthcare Professionals

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)


About the study

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. 18 to 55 years of age
  2. Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  3. At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  4. EDSS score of 0 to 5.5 (inclusive)
  5. Neurologically stable within 1 month


Exclusion Criteria:

  1. Diagnosis of primary progressive multiple sclerosis (PPMS)
  2. Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
  3. History of clinically significant CNS disease other than MS
  4. Ongoing substance abuse (drug or alcohol)
  5. History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
  6. Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
  7. suicidal ideation or behavior
  8. Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
  9. Participants who have had a splenectomy
  10. Active clinically significant systemic bacterial, viral, parasitic or fungal infections
  11. Positive results for syphilis or tuberculosis testing
  12. Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
  13. Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
  14. Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
  15. History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or participants with moderate or severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
  16. History of severe renal disease or creatinine level
  17. Participants at risk of developing or having reactivation of hepatitis

Hematology parameters at screening:

  1. Hemoglobin: < 10 g/dl (<100g/L)
  2. Platelets: < 100000/mm3 (<100 x 109/L)
  3. Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
  4. White blood cells: <3 000/mm3 (<3.0 x 109/L)
  5. Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
  6. B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  7. History or current diagnosis of significant ECG abnormalities
  8. Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment (prior to randomization)
  9. Use of other investigational drugs
  10. Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
  11. History of gastrointestinal bleeding
  12. Major surgery within 8 weeks prior to screening
  13. History of hypersensitivity to any of the study drugs or excipients
  14. Pregnant or nursing (lactating) female participants, prior to randomization
  15. Women of childbearing potential not using highly effective contraception
  16. Sexually active males not agreeing to use condom
  17. Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
  18. Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• patient who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsing Multiple Sclerosis

Age (in years)

18 - 55


Phase 3

Participants needed


Est. Completion Date

Oct 30, 2030

Treatment type



Novartis identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.